Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study
2008

TNF Blockade and HMGB1 Expression in Rheumatoid Arthritis

Sample size: 9 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sundberg Erik, Grundtman Cecilia, af Klint Erik, Lindberg Johan, Ernestam Sofia, Ulfgren Ann-Kristin, Harris Helena Erlandsson, Andersson Ulf

Primary Institution: Karolinska Institutet/Karolinska University Hospital

Hypothesis

Does TNF blockade affect the expression of HMGB1 in rheumatoid arthritis patients?

Conclusion

TNF-blocking therapy with infliximab does not significantly alter HMGB1 expression in rheumatoid arthritis patients.

Supporting Evidence

  • HMGB1 expression did not change significantly after infliximab treatment.
  • Clinical response to infliximab therapy was not correlated with changes in HMGB1 levels.
  • Inflammation signs persisted despite TNF blockade.

Takeaway

The study looked at whether a treatment for arthritis changes a specific protein related to inflammation, and it found that the treatment didn't really change that protein's levels.

Methodology

Synovial tissue was sampled from patients before and after infliximab therapy, and HMGB1 expression was analyzed using immunohistochemistry and RT-PCR.

Potential Biases

Potential bias due to the small number of patients and the subjective nature of histological scoring.

Limitations

The study had a small sample size and only included patients with knee arthritis.

Participant Demographics

Nine patients (7 females, 2 males) with a median age of 57 years and a median disease duration of 6 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar2387

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication